Harnessing drug/radiation interaction through daily routine practice: Leverage medical and methodological point of view (MORSE 02-17 study). Issue 3 (December 2018)

• Record Type: Journal Article
• Authors: Vallard, A.; Rancoule, C.; Espenel, S.; Garcia, M.-A.; Langrand-Escure, J.; He, M.Y.; Ben Mrad, M.; El Meddeb Hamrouni, A.; Ouni, S.; Trone, J.-C.; Rehailia-Blanchard, A.; Guillaume, E.; Vial, N.; Riocreux, C.; Guy, J.-B.; Magné, N.
• Is Part Of: Radiotherapy and oncology. Volume 129:Issue 3(2018)
• Page Start: 471
• Page End: 478
• Publication Date: 2018-12
• Subjects: Radiation therapy -- Non-anti-cancer treatments -- Treatment interactions -- Oncogenic pathways -- Clinical trials; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2018.06.010
• Languages: English
• ISSNs: 0167-8140

Abstract

Abstract: Background: Safety profile of the interaction between anticancer drugs and radiation is a recurrent question. However, there are little data regarding the non-anticancer treatment (NACT)/radiation combinations. The aim of the present study was to investigate concomitant NACTs in patients undergoing radiotherapy in a French comprehensive cancer center. Methods: A prospective cross-sectional study was conducted. All cancer patients undergoing a palliative or curative radiotherapy were consecutively screened for six weeks in 2016. Data on NACTs were collected. Results: Out of 214 included patients, a NACT was concomitantly prescribed to 155 patients (72%), with a median number of 5 NACTs per patient (range: 1–12). The most prescribed drugs were anti-hypertensive drugs (101 patients, 47.2%), psychotropic drugs ( n = 74, 34.6%), analgesics ( n = 78, 36.4%), hypolipidemic drugs ( n = 57, 26.6%), proton pump inhibitors ( n = 46, 21.5%) and antiplatelet drugs ( n = 38, 17.8%). Although 833 different molecules were reported, only 20 possible modifiers of cancer biological pathways (prescribed to 74 patients (34.5%)) were identified. Eight out of the 833 molecules (0.9%), belonging to six drug families, have been investigated in 28 ongoing or published clinical trials in combo with radiotherapy. They were prescribed to 63 patients (29.4%). Conclusion: Drug-radiation interaction remains a subject of major interest, not only for conventional anticancer drugs, but also for NACTs. New trial designs are thus required.